Product Description
Acorafloxacin (JNJ-Q2) is a fluoroquinolone that was developed by Furiex Pharmaceuticals (a subsidiary of Forest Laboratories) for the treatment of complicated skin and and soft tissue infections. JNJ-Q2 has excellent in vitro and in vivo activity against a variety of Gram-positive and Gram-negative organisms. In vitro studies indicate that JNJ-Q2 has potent activity against pathogens responsible for acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP), such as Staphylococcus aureus and Streptococcus pneumoniae. (Sourced from: https://drugs.ncats.io/drug/070SV15RJA)
Mechanisms of Action: Bacterial Growth Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous, Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Furiex
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Communicable Diseases|Skin Diseases, Bacterial|Pneumonia, Bacterial
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2010-021574-11 |
2010-021574-11 | P2 |
Completed |
Pneumonia, Bacterial |
2011-10-11 |
2022-03-13 |
Treatments |
|
NCT01198626 |
32729463CAP2001 | P2 |
Terminated |
Pneumonia, Bacterial |
2011-10-01 |
2024-11-27 |
Primary Endpoints|Treatments |
|
NCT01128530 |
Zyvox | P2 |
Completed |
Communicable Diseases|Skin Diseases, Bacterial |
2010-12-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|